Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 11/20 | 0.33 |
| ▸ | MAOB | P27338 | 11/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23417376 | 0.83 | KDM4E (0.35) | ALDH1A1KDM4ECYP3A4MAPTALOX15 | |
| SCHEMBL1401942 | 0.77 | MAOA (0.48) | ALDH1A1KDM4EMAPTMAOAMAOB | |
| SCHEMBL14849265 | 0.74 | HPGD (0.46) | ALDH1A1KDM4ECYP3A4MAPTALOX15 | |
| SCHEMBL12376488 | 0.74 | MAOA (0.56) | KDM4EMAOAMAOBPRKCICYP2A6 | |
| SCHEMBL21659213 | 0.70 | MAOA (0.50) | MAOAMAOBPRKCICYP2A6BAZ2B | |
| SCHEMBL8599617 | 0.69 | PBRM1 (0.53) | ALDH1A1KDM4EMAPTMAOAMAOB | |
| SCHEMBL20841064 | 0.67 | MAOA (0.37) | ALDH1A1KDM4ECYP3A4MAOAMAOB | |
| SCHEMBL1856486 | 0.66 | HSD17B10 (0.53) | KDM4EMAOAMAOBPRKCIBAZ2B | |
| SCHEMBL10249135 | 0.66 | LMNA (0.38) | ALDH1A1KDM4ECYP3A4MAPTALOX15 | |
| SCHEMBL23789055 | 0.64 | MAOA (0.53) | MAOAMAOBPRKCICYP2A6BAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | ALDH1A1 1472/4885KDM4E 877/4885CYP3A4 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.